JPWO2020086730A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020086730A5 JPWO2020086730A5 JP2021521976A JP2021521976A JPWO2020086730A5 JP WO2020086730 A5 JPWO2020086730 A5 JP WO2020086730A5 JP 2021521976 A JP2021521976 A JP 2021521976A JP 2021521976 A JP2021521976 A JP 2021521976A JP WO2020086730 A5 JPWO2020086730 A5 JP WO2020086730A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- amino acid
- acid sequence
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 60
- 102100003919 ACVR1 Human genes 0.000 claims 42
- 101700044023 ACVR1 Proteins 0.000 claims 42
- 101700040920 ALK2 Proteins 0.000 claims 42
- 101710037844 cyp52M1 Proteins 0.000 claims 42
- 102000004965 antibodies Human genes 0.000 claims 30
- 108090001123 antibodies Proteins 0.000 claims 30
- 150000001413 amino acids Chemical class 0.000 claims 19
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 4
- 208000007502 Anemia Diseases 0.000 claims 1
- 208000003432 Bone Disease Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000003452 Multiple Hereditary Exostosis Diseases 0.000 claims 1
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862749463P | 2018-10-23 | 2018-10-23 | |
| US62/749,463 | 2018-10-23 | ||
| PCT/US2019/057679 WO2020086730A1 (en) | 2018-10-23 | 2019-10-23 | Alk2 antibodies and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022505585A JP2022505585A (ja) | 2022-01-14 |
| JPWO2020086730A5 true JPWO2020086730A5 (zh) | 2022-10-18 |
Family
ID=70331231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521976A Pending JP2022505585A (ja) | 2018-10-23 | 2019-10-23 | Ａｌｋ２抗体及びその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210253720A1 (zh) |
| EP (1) | EP3870613A4 (zh) |
| JP (1) | JP2022505585A (zh) |
| KR (1) | KR20210088591A (zh) |
| CN (1) | CN113366019A (zh) |
| AU (1) | AU2019364415A1 (zh) |
| BR (1) | BR112021007660A2 (zh) |
| CA (1) | CA3116900A1 (zh) |
| IL (1) | IL282424A (zh) |
| WO (1) | WO2020086730A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022009769A (es) | 2020-02-11 | 2022-11-09 | Regeneron Pharma | Anticuerpos anti-acvr1 y usos de los mismos. |
| WO2022240948A1 (en) * | 2021-05-11 | 2022-11-17 | Keros Therapeutics, Inc. | Methods of using alk2 and alk3 antibodies |
| WO2023081212A1 (en) * | 2021-11-02 | 2023-05-11 | Keros Therapeutics, Inc. | Methods of using alk2 inhibitors |
| US20240150474A1 (en) * | 2022-10-27 | 2024-05-09 | Regeneron Pharmaceuticals, Inc. | Anti-acvri antibodies and their use in the treatment of trauma-induced heterotopic ossification |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2570458C (en) * | 2004-06-09 | 2014-05-20 | Technion Research & Development Foundation Ltd. | Antibodies for selective apoptosis of cells |
| US20160075772A1 (en) * | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| EP3252074A4 (en) * | 2015-01-30 | 2018-07-11 | Saitama Medical University | Anti-alk2 antibody |
| US10620204B2 (en) * | 2015-03-26 | 2020-04-14 | Vanderbilt University | Antibody-mediated neutralization of Ebola viruses |
-
2019
- 2019-10-23 AU AU2019364415A patent/AU2019364415A1/en active Pending
- 2019-10-23 WO PCT/US2019/057679 patent/WO2020086730A1/en unknown
- 2019-10-23 BR BR112021007660-3A patent/BR112021007660A2/pt unknown
- 2019-10-23 CA CA3116900A patent/CA3116900A1/en active Pending
- 2019-10-23 CN CN201980085459.7A patent/CN113366019A/zh active Pending
- 2019-10-23 JP JP2021521976A patent/JP2022505585A/ja active Pending
- 2019-10-23 KR KR1020217015329A patent/KR20210088591A/ko active Search and Examination
- 2019-10-23 EP EP19877108.1A patent/EP3870613A4/en active Pending
-
2021
- 2021-04-19 IL IL282424A patent/IL282424A/en unknown
- 2021-04-22 US US17/237,240 patent/US20210253720A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5047996B2 (ja) | 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法 | |
| CA2117477C (en) | Multivalent single chain antibodies | |
| JP6591964B2 (ja) | Ｉｃｏｓｌへの治療上の標的特異的ｖｎａｒドメインの単離 | |
| CN105229160B (zh) | 工程化的抗-TGF-β抗体及抗原结合片段 | |
| JP2007514419A5 (zh) | ||
| JP2022105138A5 (zh) | ||
| JP2018537966A5 (zh) | ||
| JP2011212022A (ja) | Ｄｋｋ−１に対する抗体 | |
| JP2019527194A5 (zh) | ||
| Eilat et al. | Structure-function correlates of autoantibodies to nucleic acids. Lessons from immunochemical, genetic and structural studies | |
| EA012835B1 (ru) | Антитела против фактора роста эндотелия сосудов (vegf) и способы их применения | |
| JP2012504401A5 (zh) | ||
| JP2010509931A5 (zh) | ||
| JP2009529915A5 (zh) | ||
| JP2019511911A5 (zh) | ||
| JP2009519720A5 (zh) | ||
| JP2022126804A5 (zh) | ||
| WO2021012195A1 (zh) | 可结合sftsv的纳米抗体及其应用 | |
| JP2024016201A5 (zh) | ||
| JPWO2020069028A5 (zh) | ||
| JP2006521088A5 (zh) | ||
| JP2020535811A5 (zh) | ||
| JP2020505919A5 (zh) | ||
| JPWO2020086730A5 (zh) | ||
| CA2283540A1 (en) | Anti-fas antibodies |